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Background: To improve the utility of PubChem, a public repository containing biological activities of small
molecules, the PubChem3D project adds computationally-derived three-dimensional (3-D) descriptions to the
small-molecule records contained in the PubChem Compound database and provides various search and analysis
tools that exploit 3-D molecular similarity. Therefore, the efficient use of PubChem3D resources requires an
understanding of the statistical and biological meaning of computed 3-D molecular similarity scores between
molecules.
Results: The present study investigated effects of employing multiple conformers per compound upon the 3-D
similarity scores between ten thousand randomly selected biologically-tested compounds (10-K set) and between
non-inactive compounds in a given biological assay (156-K set). When the “best-conformer-pair” approach, in which
a 3-D similarity score between two compounds is represented by the greatest similarity score among all possible
conformer pairs arising from a compound pair, was employed with ten diverse conformers per compound, the
average 3-D similarity scores for the 10-K set increased by 0.11, 0.09, 0.15, 0.16, 0.07, and 0.18 for STST-opt, CTST-opt,
ComboTST-opt, STCT-opt, CTCT-opt, and ComboTCT-opt, respectively, relative to the corresponding averages computed
using a single conformer per compound. Interestingly, the best-conformer-pair approach also increased the average
3-D similarity scores for the non-inactive–non-inactive (NN) pairs for a given assay, by comparable amounts to
those for the random compound pairs, although some assays showed a pronounced increase in the per-assay NN-
pair 3-D similarity scores, compared to the average increase for the random compound pairs.
Conclusion: These results suggest that the use of ten diverse conformers per compound in PubChem bioassay
data analysis using 3-D molecular similarity is not expected to increase the separation of non-inactive from random
and inactive spaces “on average”, although some assays show a noticeable separation between the non-inactive
and random spaces when multiple conformers are used for each compound. The present study is a critical next
step to understand effects of conformational diversity of the molecules upon the 3-D molecular similarity and its
application to biological activity data analysis in PubChem. The results of this study may be helpful to build search
and analysis tools that exploit 3-D molecular similarity between compounds archived in PubChem and other
molecular libraries in a more efficient way.* Correspondence: bolton@ncbi.nlm.nih.gov
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PubChem [1-4] is a public repository for biological activ-
ities of small molecules, consisting of three primary
databases: PubChem Substance, PubChem Compound,
and PubChem BioAssay. The PubChem Substance data-
base (record identifier: SID) archives chemical informa-
tion provided by individual data depositors, and the
PubChem Compound database (record identifier: CID)
contains the unique chemical structure contents extracted
from the PubChem Substance database. Biological testing
results of small molecules are archived in the PubChem
BioAssay database (record identifier: AID). PubChem
is a sizeable system with more than 92 million sub-
stance descriptions, 32 million unique small mole-
cules, 620 thousand biological assays, and 170 million
result outcomes (results from a substance tested in
an assay is a result outcome). For efficient use of this
enormous amount of information, PubChem provides
various search and analysis tools to assist users in lo-
cating desired information.
The PubChem3D project [5-11] augments the utility
of PubChem, by adding computed three-dimensional
(3-D) descriptions to about 90% of the small molecules
contained in the PubChem Compound database [6,11].
Each of these may include multiple 3-D conformations that
are sampled to remove redundancy, guaranteeing a mini-
mum (non-hydrogen atom pair-wise) root-mean-square
distance (RMSD) between conformers. In addition, a di-
verse conformer ordering gives a maximal description of
the conformational diversity of a molecule when using only
a subset of sampled conformers [8,11]. A pre-computed
search per compound record (called “Similar Conformers”)
[8,11] gives immediate access to a set of 3-D similar
compounds in PubChem and their respective superposi-
tions. Systematic augmentation of PubChem resources
to include a computed 3-D similarity layer grants users
new capabilities to search, subset, visualize, analyze, and
download data [11].
A goal of PubChem3D is to build a publicly accessible
platform for virtual screening and biological activity ana-
lysis that exploits 3-D molecular similarity. However,
there are many issues to address to achieve this goal, as
discussed in a recent review by Sutherland et al. [12]
One of the issues is that there is no obvious answer to
what similarity threshold value should be used to deter-
mine whether two molecules are structurally similar.
Our previous study [10] attempted to address this ques-
tion in part, by investigating the distributions of the
Rapid Overlay of Chemical Structures (ROCS) [13-21]-
based 3-D similarity scores used in PubChem3D [8,10,11]
between 270 billion unique compound pairs arising from
734,485 biologically tested compounds (referred to as the
734-K set hereafter) using a single conformer per com-
pound. [See the Methods section for the definition of six3-D similarity score types used in PubChem3D.] These
distributions allow one to perform a statistical significance
test that considers the null hypothesis that a particular
similarity score between two molecules occurs by chance.
The 3-D similarity score matrices generated were used to
investigate structural differences between “non-inactives”
and “inactives” for each of 1,389 bioassays archived in the
PubChem BioAssay database at the time. [Note that the
term “non-inactive” is defined as anything not specified to
be “inactive” by the PubChem depositor and is used in
place of “active”, since the definition of an “active” is not
always specified in PubChem and many “non-inactives”
are indeed “active”. More detailed explanation about the
use of the non-inactives is given in the Methods section].
Although some PubChem assays showed a very clear struc-
tural separation between the non-inactives and the inactives
in terms of 3-D similarity, the overall average similarity
score for non-inactive–non-inactive (NN) pairs was found
to be very similar to that for non-inactive–inactive (NI)
pairs, indicating minimal or no difference between the NN
and NI pairs in terms of 3-D similarity in general.
Although the previous study [10] provides an import-
ant statistical guideline for 3-D similarity search used in
PubChem, there is still much room for improvement.
For example, the previous study employed a single con-
former per compound, which may not be sufficient for
reliable evaluation of 3-D similarity between compounds,
as the choice of a different conformer may yield substan-
tially different similarity values and makes the selection of
an appropriate conformer a significant consideration. An
important characteristic of 3-D similarity methods,
compared to 2-D similarity methods, is that 3-D simi-
larity methods are applied at a conformer level, not at
a compound level, to enable consideration of various
distinct molecular conformations in 3-D space that
may be biologically relevant. This suggests that, for
3-D similarity methods to provide biologically meaning-
ful results, the conformer generation program employed
should be able to routinely reproduce known “bioactive”
conformers (e.g., an experimentally-derived ligand con-
formation of a chemical bound in a protein crystal struc-
ture binding pocket). Indeed, many strategies have been
developed for high-quality computational prediction of
bioactive conformation of molecules [6,13,22-28]. A com-
mon approach to bioactive conformer generation is to
sample energetically-accessible representatives that cover
the biologically-accessible conformational space of a mol-
ecule. In general, the count of potentially relevant bio-
active conformers increases as a function of molecular
size and flexibility, making the count of conformers in a
conformer ensemble an important factor to determine the
quality of the ensemble; as the greater the count, the
greater the probability of finding a representative con-
former sufficiently similar to a relevant bioactive conformer
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former model consists of up to 500 conformers (with an
average of 115 conformers) [11]. However, for tractability
reasons, many PubChem3D services allow only up to ten
“diverse” conformers per compound per request [11]. Note
that a diverse conformer ordering gives a maximal descrip-
tion of the conformational diversity of a molecule when
only a subset of available conformers is used [11].
Although many studies have investigated on the qual-
ity of various conformer model generators [13,22,28-31],
a relatively few studies have dealt with the effects of the
size of the conformer models upon the ligand-based
3-D virtual screening and biological activity analysis
[15,32,33]. Recently, Kirchmair et al. [32] examined
the impact of the quality of conformer models upon
the hit list from pharmacophore-based and shape-
based 3-D virtual screenings against four different protein
targets: cyclin-dependent kinase 2 (CDK2), p38 mitogen-
activated protein (MAP) kinase, peroxisome proliferator-
activated receptor γ (PPAR-γ), and Factor Xa. It was found
that, whereas the pharmacophore-based screening using
CATALYST [34,35] was able to identify the greatest
number of known actives even with very small con-
former ensembles, the shape-based screening using
ROCS showed an increased accuracy with larger con-
former models. On the contrary, Hawkins et al. [15]
reported that the ROCS-based virtual screening using a
single conformation for a query molecule outperforms a
pharmacophore modeling using the pharmacophores
developed from multiple active compounds (up to 20).
In addition, the same study [15] also reported that the
performance of ROCS was not affected by whether a
computationally-generated low-energy conformer or
experimentally determined protein-bound structure was
used as a single-conformer query. In this regard, a study on
pharmacophore-based 3-D searching by Fox et al. [33] is
also noteworthy, which examined the effect of conformer
sampling upon within- and between-class similarity across
seven different pharmacological classes containing 88 com-
pounds in total. Including more conformations in pharma-
cophore multiplet bitmaps was found to increase both the
within-class and between-class similarities, the net result
being that the ratio between the two falls off as more and
more conformations are included in the calculations. Over-
all, there is no consensus on the effects of the size of the
conformer models upon ligand-based 3-D virtual screening
and biological activity analysis and how many conforma-
tions should be considered in general.
The present study investigates effects of employing mul-
tiple diverse conformers per compound upon 3-D similar-
ity computation (often referred to here as “multiple-
conformer effects”) in two parts. The first part examines
the question: how will employing multiple conformers per
compound affect the 3-D similarity score between tworandomly selected biologically-tested compounds? In the
second part of the study, an attempt is made to answer
the question: can one find a greater separation between
inactives and non-inactives in PubChem bioassays on
average when multiple conformers are used for each com-
pound? Given that it is beyond our computational means
to rigorously examine this question using all PubChem3D
conformers, the approach used to tackle this second ques-
tion involves constructing per-assay distributions of 3-D
similarity scores for NN pairs using both a single con-
former per compound and ten diverse conformers per
compound and comparing them with equivalent results
for random compound pairs of biologically tested com-
pounds. In addition, multiple-conformer effects upon the
separation between the non-inactive and inactive spaces
are inferred based on the results of this study.
Results
Definitions and notations
In the present study, 3-D similarity computations that em-
ploy a single conformer per compound and multiple di-
verse conformers per compound are referred to as the
“single-conformer approach” and the “multiple-conformer
approach”, respectively. The multiple-conformer approach
is further classified into two different approaches: the “best-
conformer-pair” approach and the “all-conformer-pair”
approach. In the best-conformer-pair approach, a similarity
score between a single conformer and a compound
(or between two compounds), where each compound
has multiple diverse conformations, is represented by
the greatest similarity score among all conformer pairs
considered per conformer-compound pair (or compound-
compound pair). In the all-conformer-pair approach, one
may treat each of the individual conformer pairs as if
it were a unique compound pair. These two different
methods for the multiple-conformer approach were
employed to help simulate different database search or
analysis strategies using 3-D molecular similarity. The
five different 3-D similarity usage scenarios considered
in this study are summarized in Table 1.
As described in the Methods section, the six different
score types were considered: shape-Tanimoto (ST), color-
Tanimoto (CT), and combo-Tanimoto (ComboT) for
each of the ST- and CT-optimizations. For conveni-
ence, superscript “ST-opt” or “CT-opt” is used to
indicate whether the similarity score is estimated in the
ST-optimized alignment or in the CT-optimized alignment
(i.e., STST-opt, CTST-opt, ComboTST-opt, STCT-opt, CTCT-opt, and
ComboTCT-opt), and the similarity scores from the single-
conformer and multiple-conformer approaches are denoted
with subscripts “single” and “multi”, respectively. Similarly,
subscripts “best” and “all” are used to indicate the best-
conformer-pair approach and all-conformer-pair ap-
proach, respectively. For example, STbest
CT-opt represents
Table 1 Different 3-D similarity search (or analysis) scenarios considered
Search
Scenario
Query Conformer model Description
A Compound Single conformer Similarity scores for a compound “query” compared to those of the “database” compounds,
both computed using a single conformer per compound.
B Compound Multiple conformer,
All-conformer-pair approach
Similarity scores that one may expect when each “query” conformer is compared to a set of
multiple diverse conformers of the “database” compounds, using the “all-conformer-pair”
approach. That is, all unique conformer pairs contribute to the average and standard
deviation of the resulting similarity scores.
C Conformer Multiple conformer,
All-conformer-pair approach
Similarity scores that one may expect when a single “query” conformer is compared to a set
of multiple diverse conformers of the “database” compounds, using the “all-conformer-pair”
approach. That is, all unique conformer pairs contribute to the average and standard
deviation of the resulting similarity scores.
D Conformer Multiple conformer,
Best-conformer-pair approach
Similarity scores that one may expect when a single “query” conformer is compared to a set
of multiple diverse conformers of the “database” compounds using the “best-conformer-pair”
approach. That is, only the conformer pair with the greatest similarity per conformer-
compound pair contributes to the average and standard deviation of the resulting similarity
scores.
E Compound Multiple conformer,
Best-conformer-pair approach
Similarity scores that one may expect when each “query” conformer is compared to a set of
multiple diverse conformers of the “database” compounds using the “best-conformer-pair”
approach. That is, only the conformer pair with the greatest similarity per compound-
compound pair contributes to the average and standard deviation of the resulting similarity
scores.
Five different conformer handling scenarios considered in this study, where the 3-D similarity “query” is the entity being compared to a “database” of compound
conformers.
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approach and CTall
ST-opt indicates the ST-optimized CT score
using the all-conformer-pair approach. ComboTsingle
ST-opt indi-
cates the ST-optimized ComboT score from the single-
conformer-per-compound model. The word “XT” is
used when we refer to any of the similarity measures
(i.e., ST, CT, and ComboT), or to a similarity score in
a general sense.Datasets
Two different compound datasets were used in the present
study: the 10-K set and the 156-K set. The 10-K set
contains 10,000 biologically tested compounds randomly
selected from the 734-K set used in the previous study [10].
The 156-K set consists of 156,232 CIDs that had com-
putationally derived 3-D conformer models available in
PubChem3D and that were non-inactive in at least one
bioassay archived in the PubChem Bioassay database
(as of January 25, 2010). The construction of these
datasets is described in more detail in the Methods sec-
tion, and the PubChem Compound CIDs included in
the two sets are available in Additional files 1 and 2. In
Table 2, the 3-D molecular descriptors for the two
datasets (10-K and 156-K) are compared with those of
the 734-K set and the entire PubChem3D contents [10].
Considering the average and standard deviations of
the molecular descriptors, the two datasets used in
the present study have property profiles nearly identical to
those in the previously studied 734-K set and the entire
PubChem3D contents, with the average molecular propertyand first standard deviation of each property almost com-
pletely overlapping the other datasets.Similarity scores for the randomly selected conformer
pairs
To investigate effects of employing multiple conformers
per compound upon the 3-D similarity score between
randomly selected biologically-tested compounds, the
distributions of the 3-D similarity scores between the
10,000 compounds in the 10-K set were constructed
using both the single-conformer and multiple-conformer
approaches. The resulting 3-D similarity score distribu-
tions are shown in Figures 1, 2, 3, 4, and their averages
and standard deviations are summarized in Table 3. For
the single-conformer approach (Figure 1, corresponding
to Scenario A in Table 1), the similarity score distributions
for the unique conformer-conformer pairs and the unique
compound-compound pairs are identical (since only one
conformer per compound is considered). For the multiple-
conformer approach, however, three different distributions
were generated: the unique conformer-conformer pairs
(Figure 2, Scenario B), the unique conformer-compound
pairs (Figure 3, Scenario D), and the unique compound-
compound pairs (Figure 4, Scenario E). Note that the
3-D similarity scores for the unique conformer-compound
pairs (in Figure 3) and unique compound-compound pairs
(in Figure 4) were computed using the “best-conformer-
pair” approach, meaning that only the greatest similarity
score was chosen from all relevant conformer pairs
[i.e., up to 10 (= 1 × 10) conformer-conformer pairs
Table 2 Summary statistics of chemical structure
descriptors





24.5 ± 6.4 25.1 ± 6.4 24.6 ± 6.4 26.3 ± 7.0
Rotatable
bond count
5.5 ± 2.7 5.5 ± 2.8 5.5 ± 2.7 6.8 ± 3.0
Effective
rotor count
6.1 ± 2.8 6.1 ± 2.9 6.1 ± 2.8 7.4 ± 3.0
RMSDthresh 0.8 ± 0.2 0.8 ± 0.2 0.8 ± 0.2 0.9 ± 0.3
Monopole
volume (Å3)
475.4 ± 124.7 487.0 ± 123.3 474.1 ± 124.0 509.0 ± 137.1
Qx (Å
5) 13.8 ± 6.9 14.3 ± 7.2 12.6 ± 7.0 13.6 ± 7.8
Qy (Å
5) 3.5 ± 1.6 3.6 ± 1.6 3.3 ± 1.6 3.6 ± 1.8
Qz (Å
5) 1.4 ± 0.6 1.4 ± 0.6 1.3 ± 0.6 1.5 ± 0.6
Total feature
count









1.1 ± 1.0 1.2 ± 1.0 1.1 ± 1.0 1.2 ± 1.0
Anion count 0.2 ± 0.4 0.2 ± 0.4 0.2 ± 0.4 0.2 ± 0.4
Cation count 0.6 ± 0.8 0.8 ± 0.9 0.6 ± 0.8 0.7 ± 0.9
Hydrophobe
count
0.3 ± 0.6 0.3 ± 0.6 0.3 ± 0.6 0.5 ± 0.8
Ring count 3.0 ± 1.2 3.1 ± 1.2 3.0 ± 1.2 3.0 ± 1.3
The average and standard deviation of heavy atom count, rotatable bond
count, effective rotor count, sampling RMSD (RMSDthresh), monopole volume,
three steric shape quadrupole components (Qx, Qy, and Qz), and feature
counts (by total and each of the six feature types) for 10,000 randomly
selected biologically tested compounds (10-K set), 156,232 non-inactive
compounds (156-K set), 734,486 CIDs biologically tested compounds (734-K
set) and the entire PubChem3D contents (26,157,365 CIDs as of September
2010). The data for the 734-K set and the entire PubChem3D contents are
from Ref. [10]. The RMSDthresh and effective rotor count were computed using
Equations (1) and (3), respectively [see the Methods section].
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conformer-conformer pairs per compound-compound
pair, because ten diverse conformers per compound were
used].
As shown in Table 3 and Figure 1, when the single-
conformer approach (Scenario A) was employed, the
average similarity score for the “unique” compound-
compound pairs from the 10-K set was 0.54, 0.07, 0.62,
0.41, 0.18, and 0.59 for STST-opt, CTST-opt, ComboTST-opt,
STCT-opt, CTCT-opt, and ComboTCT-opt, respectively. These
averages for the 10-K set are exactly identical to
those for the 734-K set determined from the previous
study [10], reflecting the fact that 10-K set was con-
structed from random sampling of the 734-K set, andimportantly suggesting that the 10-K set is represen-
tative of the 734-K set.
Perhaps surprising to some, the distributions (Figure 2)
and statistics (Table 3) of the 3-D similarity scores from the
“all-against-all” conformer comparison using multiple di-
verse conformers per compound (Scenario B) are essentially
identical to those computed with a single conformer per
compound (Figure 1), showing that the single-conformer
and multiple-conformer “all-against-all” comparisons yield
near identical random distributions. This suggests that the
3-D similarity distributions for random conformer pairs of
biologically tested chemicals, whether using a single con-
former or multiple conformers, is a general result. It also
suggests that further analysis of the 10-K set may be a rea-
sonable representation of a much larger bioactivity data set
corpus and that conclusions drawn from the 10-K set may
be applicable in a more general sense as the 10-K set repre-
sents the 734-K set and is possibly extensible to or may
otherwise represent the analysis of all biologically tested
compounds in PubChem.
Comparison of Figure 3 to Figure 1 is rather telling.
If one uses a single conformer query against a multi-
conformer database (Scenario D), as is often done in a simi-
larity query of a 3-D database, e.g., for virtual screening pur-
poses, the average random distribution values increase by
0.06, 0.05, 0.08, 0.09, 0.04, and 0.10 for STST-opt, CTST-opt,
ComboTST-opt, STCT-opt, CTCT-opt, and ComboTCT-opt,
respectively, as a result from picking the best conformer
pair out of the maximum of ten diverse conformers consid-
ered per database compound. By comparing Figure 4 to
Figure 3, one sees that, if a multi-conformer 3-D query is
used against a multi-conformer 3-D database (Scenario E),
there is a further increase over the results of Scenario D in
that the average random distribution values increase by
0.05, 0.04, 0.07, 0.07, 0.03, and 0.08 for STST-opt, CTST-opt,
ComboTST-opt, STCT-opt, CTCT-opt, and ComboTCT-opt,
respectively, as a result of an additional order of magnitude
increase in diverse conformer pairs considered per com-
pound query. One keen observation is that, as the con-
former pair count considered per compound pair increases
from 1 to a maximum of 100, the width of the distribution
curves (i.e., the variation of the similarity scores) does not
change very much, whereas the location of the distribu-
tion curves (i.e., the average of the similarity scores)
does. Furthermore, the average similarity score differ-
ences between the potential maximums of 10 and 100
conformer pairs per compound pair (Figure 3 vs. Figure 4)
are smaller by 0.01-0.02 than those between 1 and a poten-
tial maximum of 10 conformer pairs per compound pair
(Figure 1 vs. Figure 3), indicating a decrease in the rate of
the similarity score change as a function of the order
of magnitude of the conformer pair count increase.
[This observed reduction could also partially reflect
an effective reduction in the average count of diverse
Figure 1 Similarity distributions for “single-conformer” (Scenario A) approach. Binned distributions in 0.01 increments of the 3-D similarity
scores for the unique “conformer-conformer” pairs arising from 10,000 randomly selected biologically tested compounds (10-K set), computed
using a single conformer per compound for (a) ST-optimized and (b) CT-optimized superpositions.
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not every compound considered will have ten diverse
conformers associated. However, considering the 10-K
set averages 9.0 diverse conformers per compound, this
effect should not be large but would be of increasing
importance as the logarithmic count of diverse confor-
mers per compound is further increased.] This reduc-
tion in the rate of the average similarity score increase
as a function of the logarithm increase of conformer
pairs suggests that the similarity score change will
eventually plateau (i.e., at some point, consideration of
additional diverse conformers per compound will cease
to change the distribution average). This log/linear be-
havior is similar to that observed in our earlier work
[8], where a corresponding increase in the logarithmic
number of conformers resulted in a linear increase of 3-D
similarity neighbors. With that said, at ten diverseconformers per compound, there still seems to be add-
itional room for further increases in the random distribu-
tion average if one was to consider using more diverse
conformers per compound. It may be important to point
out that, since PubChem samples conformers and then
picks a diverse subset of these sampled conformers, if one
was to use conformers without sampling or picking a non-
diverse subset, there may be additional shifts or changes in
these average random distributions.
Note that the CTST-opt distribution in Figure 1 has
a second peak at CTST-opt = 0. This bimodality is
related to the definition of the CT score. If none of
the fictitious “feature” atoms used in the CT score are
proximate, it will result in a zero or near-zero CT score.
Whereas the CT-optimization maximizes the CT score,
the ST-optimization ignores it. Considering the shift in
the CTST-opt and CTCT-opt distributions is 0.11, the
Figure 2 Similarity distributions for multi-conformer “all-conformer-pair” (Scenario B) approach. Binned distributions in 0.01 increments of
the 3-D similarity scores for the unique “conformer-conformer” pairs arising from 10,000 randomly selected biologically tested compounds (10-K
set), computed using ten diverse conformers per compound and the “all-conformer-pair” approach for (a) ST-optimized and (b) CT-optimized
superpositions.
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tive CTST-opt scores, which is smaller than the smallest
possible value of the CT score. [Note that the CT
score ranges from 0 to 1 by definition.] This shift
builds up the zero counts, thus forming a second
peak at CTST-opt = 0.
To further demonstrate what one might find in various
3-D similarity search/analysis scenarios, the similarity
score matrices generated for the 10-K set were used to
investigate the average and standard deviation of the
“per-query” similarity scores for the five different scenarios
described in Table 1. Scenario A uses a single conformer
for each of the “query” and “database” compounds, and
the other four search scenarios employ up to ten diverse
conformers for each “database” compound. The “query” in
Scenario B and Scenario E is a compound that may
have up to ten diverse conformers whereas Scenario Cand Scenario D use a single conformer as a “query”.
Scenario B and Scenario C use the “all-conformer-pair”
approach, while Scenario D and Scenario E use the
“best-conformer-pair” approach. The resulting distribu-
tions from the five search scenarios are shown in Figures 5,
6, 7 for the ST, CT, and ComboT values, respectively.
Note that the “all-conformer-pair” approach effectively
treats multiple conformers of a compound as individual
compounds. For this reason, Scenario B and Scenario C,
which adopt the all-conformer-pair approach, resulted in
nearly identical average per-query similarity scores as
Scenario A, which uses a single conformer per com-
pound. These three search scenarios are conceptually
identical to constructing the distribution curves for the
unique compound-compound pair computed using the
single-conformer approach (Figure 1) and those for the
unique conformer-conformer pair computed using the
Figure 3 Similarity distributions for multi-conformer “best-conformer-pair” (Scenario D) approach. Binned distributions in 0.01 increments
of the 3-D similarity scores for the unique “conformer-compound” pairs arising from 10,000 randomly selected biologically tested compounds
(10-K set), computed using ten diverse conformers per compound and the “best-conformer-pair” approach for (a) ST-optimized and (b) CT-
optimized superpositions.
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hand, Scenario D and Scenario E, which use the “best-
conformer-pair” approach, increased the per-query simi-
larity scores. The averages for Scenario D and Scenario E
were the same as those for conformer-compound pairs
(Figure 3) and the unique compound-compound pairs
(Figure 4), respectively, computed with multiple diverse
conformers per compound.
The average per-query similarity scores in Figures 5, 6,
7 are nearly identical to the averages found in Table 3,
but the standard deviations for the per-query similarity
scores tend to be about 0.01 less than the standard
deviations in Table 3. The modes of the average values
are generally greater by 0.02-0.04 than the overall average
values for most ST and ComboT values. Figures 5, 6, 7
suggest that some structures have smaller 3-D similarity
search averages and greater standard deviations, yieldingmode values that are shifted from the overall average
values. This appears more pronounced in the case of
ST-optimized similarity score values. So, depending on the
mix of chemical structures being considered in an individ-
ual 3-D similarity search (and perhaps to the extent of
their shape and feature uniqueness), there may be consid-
erable volatility in the distribution of similarity scores be-
tween individual 3-D similarity queries. In the aggregate,
however, most biologically considered chemicals in the
10-K set (and potentially PubChem in general) appear to
have a limited range of variation in average 3-D similarity
scores and standard deviation values.
Similarity scores for the non-inactive–non-inactive pairs
A. Summary statistics
In the second part of this study, the distributions of the
3-D similarity scores between non-inactive compounds
Figure 4 Similarity distributions for multi-conformer “best-conformer-pair” (Scenario E) approach. Binned distributions in 0.01 increments
of the 3-D similarity scores for the unique “compound-compound” pairs arising from 10,000 randomly selected biologically tested compounds
(10-K set), computed using ten diverse conformers per compound and the “best-conformer-pair” approach for (a) ST-optimized and (b) CT-
optimized superpositions.
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Chem were constructed using the 156-K set and both the
single-conformer and multiple-conformer approaches, to
address the question: how will employing multiple confor-
mers per compound change the 3-D similarity scores be-
tween the non-inactive molecules for a given biological
assay? In addition, the results from this section, in conjunc-
tion with the analyses for the random compound pairs in
the previous section, provide clues to the question: does
one see (greater) separation of active and inactive spaces
when employing multiple conformers per compound, as
opposed to a single conformer per compound?
The assay-type counts for these 1,528 bioassays are
shown in Figure 8. The bioassays in the PubChem Bio-
Assay database can be classified into four categories,
according to PubChem depositor-assigned assay types:primary, confirmatory, summary, and other. Note that there
is another category in Figure 8, “Unspecified”, because the
assay-type attribute for AID records are optional, and not
required. The per-AID average and standard deviation of
the six 3-D similarity scores (i.e., STST-opt, CTST-opt,
ComboTST-opt, STCT-opt, CTCT-opt, and ComboTCT-opt)
for the NN pairs of each of the 1,528 AIDs are included in
Additional file 3, and their overall per-AID average and
standard deviation (i.e., μ[μ(XT)], σ[μ(XT)], μ[σ(XT)] and
σ[σ(XT)]; see the Methods section for the definition) are
listed in Table 4 and Table 5. The average and standard de-
viation of the differences in these per-AID values between
the single-conformer and multiple-conformer approaches
are summarized in Table 6. The distributions of the per-
AID average similarity scores for the 1,528 AIDs are shown
in Figures 9 and 10.




Nc ST CT ComboT




A 1 0.54 0.10 0.07 0.05 0.62 0.13
compound-
compound
A 1 0.54 0.10 0.07 0.05 0.62 0.13
conformer-
conformer
B 10 0.54 0.09 0.07 0.05 0.61 0.12
conformer-
compound
D 10 0.60 0.10 0.12 0.06 0.70 0.12
compound-
compound




A 1 0.41 0.11 0.18 0.06 0.59 0.14
compound-
compound
A 1 0.41 0.11 0.18 0.06 0.59 0.14
conformer-
conformer
B 10 0.40 0.11 0.18 0.06 0.58 0.13
conformer-
compound
D 10 0.50 0.10 0.22 0.06 0.69 0.13
compound-
compound
E 10 0.57 0.10 0.25 0.07 0.77 0.14
The overall average and standard deviation of the 3-D similarity score
distributions by search (or analysis) scenario. The 10-K set was used unless
otherwise indicated.
a For the 734-K set from Ref. [10].
b See Table 1 for Search Scenario description.
c N is the number of diverse conformers employed per compound.
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were also performed for a subset of the 1,528 assays, which
consists of 843 assays that have active compounds only
(without any inconclusive or unspecified compounds), and
the results are summarized in Additional file 4. Note the
minor peaks in the distributions for the best-conformer-
pair approach in Figures 9, 10. These peaks arise from the
34 National Institutes of Neurological Disorders and
Strokes (NINDS) approved drug screenings, in which
the same set of non-inactive compounds were tested
against different targets. Although they are different
assays, they do have the same set of non-inactive com-
pounds, yielding the minor peaks in Figures 9, 10. Because
these 34 assays are not included in the 843 assays, the
resulting similarity score distribution curves from the 843
assays are closer to the normal distribution than those
from the 1,528 assays. However, the two assay sets have
very similar averages and standard deviations to each
other, and hence the analysis and discussion below, which
are based on the 1,528 assay set, also hold for the 843
assay set.
Summarized in Table 6, the overall average and standard
deviation of the per-AID average similarity score differencesbetween the best-conformer-pair approach and single-
conformer approach were 0.09 ± 0.03, 0.09 ± 0.04,







CT-opt ), and μ(ComboTbest−single
CT-opt ),
respectively, indicating that the best-conformer-pair
approach gives a statistically significant increase in 3-D
similarity scores between the NN pairs, relative to those
computed using a single conformer per compound. On







CT-opt ), and μ(ComboTall−single
CT-opt ) were
−0.01 ± 0.03, −0.02 ± 0.06, −0.03 ± 0.09, −0.02 ± 0.04,
−0.01 ± 0.05, and −0.03 ± 0.09, respectively, meaning that
there were no statistically significant differences in the
average 3-D similarity scores for the NN pair between the
all-conformer-pair approach (Scenario B) and the single-
conformer approach (Scenario A).
In general, as shown in Tables 4 and 5, when going from
primary screen assays to confirmatory assays to summary
assays, the average similarity scores between the NN pairs
increase, regardless of whether a single conformer or
multiple conformers are used for each compound.
However, these increases should not be considered as
statistically meaningful because the standard deviations
of the NN-pair 3-D similarity scores also become greater
and these distributions significantly overlap.
Employing multiple conformers per compound (Scenario
E as opposed to Scenario A) increases the NN-pair 3-D
similarity scores by a similar amount for all of the primary,
confirmatory, and summary assays. For example, the
average and standard deviation of μ(ComboTbest−single
ST-opt )
were 0.16 ± 0.05, 0.15 ± 0.06, and 0.17 ± 0.06, for primary,
confirmatory, and summary assays, respectively (Table 6).
Therefore, the multiple-conformer effects upon the 3-D
similarity score of the NN pairs should be considered as
independent of the assay category.
B. Comparison between the NN-pairs and randomly
selected pairs
If one considers the data from Table 3 (i.e., the rows
labeled as “Random” in Table 4 and Table 5) and compares
them to the per-AID results, one sees that for randomly
selected biologically tested molecules the overall averages
are consistently less than the per-AID values across
all 3-D similarity optimization types and across both
single-and multi-conformer approaches, with the notable
exception of “Unspecified” assay types. This is a similar
result found in the earlier study [10] that used a single
conformer per compound.
Table 7 and Figures 11 and 12 summarize how distant
the average NN-pair similarity scores for each of the
bioassays considered are from those for randomly selected
compound pairs (from Table 3). Note that the per-AID
Figure 5 Average and standard deviation distributions for shape-Tanimoto (ST), per “query”. Binned distributions in 0.01 increments of
the average and standard deviation of the shape-Tanimoto (ST) scores per query-type for the five similarity search scenarios tested (see Table 1):
Scenario A [(a) and (b)], Scenario B [(c) and (d)], Scenario C [(e) and (f)], Scenario D [(g) and (h)], and Scenario E [(i) and (j)]. The left panels [(a), (c),
(e), (g), and (i)] are for the ST-optimized ST scores, and the right panels [(b), (d), (f), (h), and (j)] are for the CT-optimized ST scores.
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http://www.jcheminf.com/content/4/1/28NN-pair CT score average for a given assay are found as
much as 14 standard deviation units away from the corre-
sponding average for the random compound pairs, reflect-
ing that the average and standard deviation of the CT
scores for the random compound pair are less than those
of the ST or ComboT scores.
When averaged over the six different similarity score
types, the single-conformer approach resulted in 1,279AIDs (83.8%) with the NN-pair similarity scores equal to
or greater than the corresponding average for the ran-
dom compound pairs. The multiple-conformer approach
reduced this number to 1,090 AIDs (71.4%) on average,
implying a decrease in the distance of the NN-pair simi-
larity from the random compound pair similarity in gen-
eral. However, there is a minute difference between the
ST scores and the CT and ComboT scores. When multiple
Figure 6 Average and standard deviation distributions for color-Tanimoto (CT), per “query”. Binned distributions in 0.01 increments of the
average and standard deviation of the color-Tanimoto (CT) scores per query-type for the five similarity search scenarios tested (see Table 1):
Scenario A [(a) and (b)], Scenario B [(c) and (d)], Scenario C [(e) and (f)], Scenario D [(g) and (h)], and Scenario E [(i) and (j)]. The left panels [(a), (c),
(e), (g), and (i)] are for the ST-optimized CT scores, and the right panels [(b), (d), (f), (h), and (j)] are for the CT-optimized CT scores.
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Figure 7 Average and standard deviation distributions for combo-Tanimoto (ComboT), per “query”. Binned distributions in 0.01
increments of the average and standard deviation of the combo-Tanimoto (ComboT) scores per query-type for the five similarity search scenarios
tested (see Table 1): Scenario A [(a) and (b)], Scenario B [(c) and (d)], Scenario C [(e) and (f)], Scenario D [(g) and (h)], and Scenario E [(i) and (j)].
The left panels [(a), (c), (e), (g), and (i)] are for the ST-optimized ComboT scores, and the right panels [(b), (d), (f), (h), and (j)] are for the
CT-optimized ComboT scores.
Kim et al. Journal of Cheminformatics 2012, 4:28 Page 13 of 30
http://www.jcheminf.com/content/4/1/28conformers were used for each compound, there was
a decrease in the difference between the ST scores of
the NN-pairs and those of the random pairs for the
entire range. On the other hand, as shown in Table 7,
the multiple-conformer effect resulted in more
bioassays that had NN-pair CT and ComboT scoreaverages equal to or greater than the respective μ +
2σ thresholds. For example, when going from the
single conformer per compound to ten diverse con-
formers per compound, the number of bioassays with
μ(CTNN-pair
ST-opt ) ≥ μ(CTrandom
ST-opt ) + 2σ(CTrandom
ST-opt ) increases from
144 (= 1,528 − 1,384) to 153 (=1,528 − 1,375), whereas the
Figure 8 Break down of assays by type. Assay-type counts for the
1,528 bioassays considered in the present study.
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ST-opt ) ≥ μ(STrandom
ST-opt )
+ 2σ(STrandom
ST-opt ) decreases from 38 (=1,528 − 1,490)
to 28 (=1,528 − 1,500).
C. Examples of multiple-conformer effects in 3-D similarity
computation
This section presents examples that show substantial
multiple-conformer effects upon 3-D similarity between
biologically similar molecules. An underlying assump-
tion of these examples is that a similarity score at least
two standard deviations above the average similarity
score of the randomly selected conformers (i.e., greater
than μ + 2σ) is statistically significant. For example, two
compounds are considered to be structurally similar
to each other when the ComboTST-opt score between them
is greater than 0.88 and 1.03 for the single-conformer and
best-conformer-pair approaches, respectively (on the basis
of the statistical parameters in Table 3).
According to our supplementary computation, the
average and standard deviation of the 2-D similarity
scores between all compound pairs arising from the
10-K set, computed using the PubChem subgraph finger-
print [36] and Tanimoto equation [37-40], were 0.42 ± 0.13,
and hence, a pair of molecules with the 2-D similarity score
greater than 0.68 were considered to be structurally similar
to each other under the same threshold (i.e., μ + 2σ) as used
for 3-D similarity. Note that 2-D similarity methods do
not always recognize structural similarity between bio-
logically similar molecules that 3-D similarity methods
readily do [8,10,11,14,41-44].
In the examples below, each conformer of a given com-
pound will be designated with a local conformer identifier
(LID) [11], which, in conjunction with CID, allows the
user to uniquely identify each conformer in PubChem3D.For simplicity, a particular conformer of a compound is
represented by combining the corresponding CID and
LID. For example, conformer “60823.2” represents LID 2
of CID 60823, the default conformer of atorvastatin. The
default conformer of a compound record in PubChem3D
is the first diverse conformer, which is used when a single
conformer is considered for a molecule. Note that LID 1
of a compound is not necessarily the default conformer,
because the diverse conformer ordering of a compound
may or may not begin with LID 1.
An example of substantial multiple-conformer effects
upon 3-D similarity comparison can be found with the
non-inactive compounds of AID 1033 [45] (Figure 13),
an NMR-based screening to identify small molecules
that target the chaperone DnaK in E.coli [46,47]. As
shown in the dendrograms produced by the PubChem
Structure Clustering tool [11] in Figure 13, whereas
some compound pairs show 2-D similarity scores below
0.68, the 3-D ComboTST-opt similarity scores computed
using ten conformers per compound are all well above
1.03. For example, the 2-D similarity score between
CIDs 668798 and 1246750 is 0.48, and the ComboTST-opt
score computed using a single default conformer is 0.53,
implying that both the 2-D and single-conformer 3-D
similarity cases cannot recognize structural similarity be-
tween the two molecules. However, when ten diverse
conformers per compound are employed, the largest
ComboTST-opt score from all the conformer pairs is 1.21
[corresponding to the (668798.12, 1246750.25) pair],
sufficiently high enough to consider them structurally
similar to each other.
Another example in which the PubChem 3-D multi-
conformer similarity method provides an improvement
is AID 491 [48] (Figure 14), which contains in vitro
affinity data extracted from the literature for small-
molecule inhibitors tested against influenza A virus sialidase
(also known as neuraminidase) [49,50]. Figure 14 shows the
dendrograms for eight compounds selected from 60 non-
inactive compounds in AID 491 for demonstration pur-
poses. Although the eight compounds can be classified into
two clusters of compounds at a 2-D similarity threshold of
0.5, the 3-D ComboTST-opt similarity among them is greater
than 1.03 across all eight structures when ten conformers
are used for each compound. In other words, the two inde-
pendent 2-D similarity clusters, each representing a dif-
ferent chemical series, are recognized as a single 3-D
similarity cluster, which in part emphasizes the relative
strengths of the PubChem 3-D similarity method over
its PubChem 2-D similarity counterpart. The 3-D similarity
single-conformer approach, however, cannot recognize the
similarity between all eight compounds. CIDs 490518 and
505938 are the compound pair that shows the greatest
difference between the 2-D similarity score and the 3-D
CTST-opt score (0.41 vs. 1.04). Note that the conformer
Table 4 Summary statistics for per-AID shape-Tanimoto (ST)-optimized 3-D similarity
Assay type STST-opt CTST-opt ComboTST-opt
Single All Best Single All Best Single All Best
μ[μ(XT)]
Primary 0.58 0.57 0.68 0.10 0.09 0.20 0.68 0.65 0.84
Confirmatory 0.59 0.57 0.68 0.12 0.10 0.21 0.71 0.67 0.86
Summary 0.63 0.60 0.72 0.23 0.18 0.34 0.86 0.78 1.02
Other 0.58 0.57 0.67 0.11 0.08 0.21 0.68 0.65 0.84
Unspecified 0.56 0.56 0.62 0.07 0.07 0.13 0.63 0.62 0.73
All assays 0.58 0.57 0.68 0.11 0.09 0.20 0.70 0.66 0.85
Random 0.54 0.54 0.65 0.07 0.07 0.16 0.62 0.61 0.77
σ[μ(XT)]
Primary 0.04 0.03 0.04 0.06 0.03 0.09 0.09 0.05 0.12
Confirmatory 0.06 0.05 0.06 0.11 0.05 0.13 0.16 0.09 0.18
Summary 0.11 0.09 0.09 0.20 0.15 0.21 0.31 0.24 0.30
Other 0.06 0.05 0.06 0.07 0.04 0.12 0.12 0.08 0.18
Unspecified 0.04 0.04 0.04 0.03 0.02 0.03 0.06 0.05 0.06
All assays 0.06 0.04 0.06 0.09 0.05 0.11 0.14 0.09 0.17
μ[σ(XT)]
Primary 0.10 0.09 0.09 0.08 0.07 0.08 0.15 0.14 0.14
Confirmatory 0.11 0.10 0.10 0.10 0.09 0.11 0.19 0.16 0.18
Summary 0.11 0.09 0.09 0.16 0.13 0.15 0.25 0.20 0.22
Other 0.11 0.10 0.11 0.10 0.08 0.11 0.19 0.16 0.19
Unspecified 0.14 0.13 0.15 0.09 0.08 0.10 0.20 0.18 0.21
All assays 0.11 0.10 0.10 0.10 0.08 0.10 0.18 0.16 0.18
Random 0.10 0.09 0.10 0.05 0.05 0.06 0.13 0.12 0.13
σ[σ(XT)]
Primary 0.02 0.01 0.01 0.05 0.03 0.04 0.07 0.03 0.05
Confirmatory 0.02 0.02 0.03 0.06 0.04 0.06 0.08 0.05 0.07
Summary 0.04 0.01 0.03 0.10 0.06 0.08 0.14 0.06 0.10
Other 0.03 0.02 0.03 0.06 0.04 0.05 0.07 0.04 0.07
Unspecified 0.02 0.02 0.03 0.03 0.03 0.04 0.04 0.04 0.05
All assays 0.03 0.02 0.03 0.06 0.04 0.05 0.08 0.05 0.07
The overall average and standard deviation of the AID-specific average and standard deviation as a function of search scenario and per assay type classifier. “All
assays” corresponds to all assays irrespective of assay type. “Random” corresponds to the 10-K set results found from Table 3 as a means of comparison. “Single”,
“All”, and “Best” correspond to search scenarios “A”, “B”, and “E” in Table 1, respectively.
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a substantial increase in the CTST-opt score, compared to
the superposition between the default conformers 490518.1
and 505938.1.
D. Summary comparison of overall average similarity
Figure 15 compares the overall average 3-D similarity
scores for the random compound-compound pairs with
the overall average μ[μ(XT)] values for the NN and NI
pairs, computed in the present and previous studies [10].
As shown in Figure 15, the single-conformer approach
does not result in a noticeable difference between theaverage 3-D similarities for the NN pair and those for the
random compound-compound pair, with distributions that
considerably overlap. While there are individual assays
where an improvement is found (e.g., more AIDs with the
average similarity of the NN pairs 2σ away from those of
the random pairs in the case of CT and ComboT values),
the use of the multiple-conformer approach does not make
a noticeable improvement in the aggregate.
Why is this so? The lack of a more noticeable differ-
ence between the NN pairs and random pairs can be
attributed to an assumption used in the molecular simi-
larity methods and the nature of typical biological assays.
Table 5 Summary statistics for per-AID color-Tanimoto (CT)-optimized 3-D similarity
Assay type STCT-opt CTCT-opt ComboTCT-opt
Single All Best Single All Best Single All Best
μ[μ(XT)]
Primary 0.45 0.43 0.61 0.21 0.20 0.27 0.65 0.63 0.84
Confirmatory 0.47 0.44 0.61 0.22 0.21 0.29 0.69 0.65 0.87
Summary 0.52 0.49 0.66 0.32 0.31 0.40 0.84 0.79 1.03
Other 0.45 0.43 0.60 0.22 0.20 0.29 0.67 0.64 0.85
Unspecified 0.44 0.43 0.56 0.17 0.18 0.22 0.61 0.60 0.74
All assays 0.46 0.43 0.61 0.22 0.21 0.28 0.67 0.64 0.85
Random 0.41 0.40 0.57 0.18 0.18 0.25 0.59 0.58 0.77
σ[μ(XT)]
Primary 0.05 0.04 0.05 0.06 0.04 0.08 0.10 0.06 0.13
Confirmatory 0.08 0.05 0.07 0.11 0.07 0.12 0.18 0.12 0.19
Summary 0.15 0.12 0.11 0.20 0.18 0.20 0.34 0.29 0.32
Other 0.07 0.06 0.07 0.08 0.06 0.12 0.14 0.11 0.19
Unspecified 0.04 0.03 0.04 0.03 0.03 0.03 0.07 0.06 0.07
All assays 0.07 0.05 0.07 0.09 0.06 0.11 0.16 0.11 0.17
μ[σ(XT)]
Primary 0.13 0.11 0.10 0.08 0.08 0.08 0.18 0.16 0.15
Confirmatory 0.14 0.12 0.11 0.10 0.10 0.11 0.21 0.19 0.19
Summary 0.15 0.12 0.10 0.14 0.12 0.14 0.27 0.22 0.23
Other 0.14 0.12 0.12 0.11 0.10 0.11 0.21 0.18 0.20
Unspecified 0.15 0.14 0.15 0.11 0.12 0.12 0.21 0.21 0.22
All assays 0.13 0.12 0.11 0.10 0.09 0.10 0.20 0.18 0.18
Random 0.11 0.11 0.10 0.06 0.06 0.07 0.14 0.13 0.14
σ[σ(XT)]
Primary 0.02 0.01 0.02 0.04 0.03 0.03 0.06 0.04 0.05
Confirmatory 0.03 0.02 0.03 0.05 0.04 0.05 0.08 0.05 0.07
Summary 0.06 0.01 0.03 0.09 0.04 0.07 0.15 0.05 0.11
Other 0.03 0.02 0.03 0.05 0.04 0.05 0.07 0.05 0.07
Unspecified 0.02 0.02 0.02 0.03 0.04 0.03 0.05 0.05 0.05
All assays 0.03 0.02 0.03 0.05 0.04 0.05 0.07 0.05 0.07
The overall average and standard deviation of the AID-specific average and standard deviation as a function of search scenario and per assay type classifier. “All
assays” corresponds to all assays irrespective of assay type. “Random” corresponds to the 10-K set results found from Table 3 as a means of comparison. “Single”,
“All”, and “Best” correspond to search scenarios “A”, “B”, and “E” in Table 1, respectively.
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similarity principle, which states that “structurally similar
molecules are likely to have similar biological and pharma-
cological properties” [51]. An underlying assumption of
the similarity principle is that structurally similar mole-
cules tend to bind to a target macromolecule in a similar
fashion. However, not all biological assays have a well-
defined target macromolecule. For example, biological
experiments may be designed to find molecules that target
a whole cell or a whole organism, involving many different
potential binding sites, modes of action, etc. Even when
there is a well-defined target and carefully crafted assay,there is also no guarantee that the observed activity is real
or manifested in an intended way, with the potential for
molecules to bind irreversibly or otherwise denature the
experiment by being cytotoxic, a chromophore at the de-
tector wavelength, protein aggregator, etc. There is also no
guarantee, after the activity observed is validated as being
real, that the way in which two similar molecules bind will
be identical (e.g., agonist vs. antagonist vs. partial-agonist
vs. partial-antagonist). Further confusing matters, there is
no guarantee that the biologically inactive molecules are
indeed not active for a given biological target with factors
in how the assay is performed preventing or not registering
Table 6 Comparison of summary statistics of per-AID 3-D similarity
Assay type ST-optimized CT-optimized
Best – Single All – Single Best – Single All – Single
ST CT ComboT ST CT ComboT ST CT ComboT ST CT ComboT
μ[μ(XT)]
Primary 0.10 0.10 0.16 -0.01 -0.01 -0.03 0.17 0.07 0.19 -0.02 -0.01 -0.03
Confirmatory 0.09 0.09 0.15 -0.02 -0.03 -0.04 0.15 0.07 0.18 -0.03 -0.01 -0.04
Summary 0.09 0.10 0.17 -0.03 -0.05 -0.08 0.14 0.08 0.19 -0.03 -0.02 -0.05
Other 0.09 0.10 0.16 -0.01 -0.02 -0.03 0.15 0.07 0.18 -0.02 -0.01 -0.04
Unspecified 0.06 0.06 0.10 0.00 -0.01 -0.01 0.11 0.04 0.12 -0.02 0.00 -0.01
All assays 0.09 0.09 0.15 -0.01 -0.02 -0.03 0.15 0.07 0.18 -0.02 -0.01 -0.03
σ[μ(XT)]
Primary 0.02 0.04 0.05 0.02 0.04 0.06 0.03 0.03 0.05 0.03 0.03 0.06
Confirmatory 0.03 0.04 0.06 0.04 0.08 0.12 0.04 0.03 0.06 0.05 0.06 0.11
Summary 0.04 0.04 0.06 0.04 0.08 0.12 0.05 0.04 0.07 0.05 0.06 0.11
Other 0.04 0.07 0.09 0.02 0.04 0.06 0.05 0.05 0.09 0.03 0.04 0.07
Unspecified 0.01 0.01 0.02 0.02 0.01 0.02 0.02 0.01 0.02 0.02 0.01 0.03
All assays 0.03 0.04 0.06 0.03 0.06 0.09 0.04 0.03 0.06 0.04 0.05 0.09
μ[σ(XT)]
Primary 0.00 0.01 0.01 0.00 0.00 0.01 0.01 0.01 0.01 0.00 0.00 0.01
Confirmatory 0.01 0.01 0.02 0.01 0.01 0.01 0.01 0.01 0.02 0.01 0.01 0.01
Summary 0.02 0.04 0.06 0.02 0.03 0.04 0.03 0.03 0.06 0.03 0.03 0.05
Other 0.01 0.01 0.01 0.00 0.01 0.01 0.01 0.01 0.01 0.01 0.01 0.01
Unspecified 0.01 0.01 0.01 0.01 0.00 0.01 0.01 0.01 0.01 0.01 0.00 0.01
All assays 0.01 0.01 0.02 0.01 0.01 0.01 0.01 0.01 0.02 0.01 0.01 0.01
σ[σ(XT)]
Primary 0.01 0.02 0.02 0.01 0.01 0.02 0.01 0.01 0.03 0.01 0.01 0.02
Confirmatory 0.01 0.02 0.03 0.01 0.02 0.03 0.02 0.02 0.04 0.01 0.02 0.03
Summary 0.03 0.05 0.08 0.02 0.04 0.07 0.04 0.04 0.08 0.03 0.04 0.07
Other 0.01 0.02 0.02 0.01 0.01 0.02 0.01 0.02 0.03 0.01 0.01 0.02
Unspecified 0.01 0.01 0.03 0.01 0.01 0.02 0.02 0.01 0.03 0.01 0.01 0.02
All assays 0.01 0.02 0.03 0.01 0.02 0.02 0.02 0.02 0.03 0.01 0.01 0.03
The overall average and standard deviation of the AID-specific average and standard deviation of the similarity score differences between the multiple-conformer
model and single-conformer model approaches. “All assays” corresponds to all assays irrespective of type. “Single”, “All”, and “Best” correspond to search scenarios
“A”, “B”, and “E” in Table 1, respectively.
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venting accurate correlation of structural similarity with
biological activity in one form or another are nearly limit-
less but one must try nevertheless to do the best they can
with the data they have.
The 1,528 bioassays considered in this study were
selected without considering any complexities, and there-
fore, there is no guarantee that the observed biological
similarity between bioactive molecules in these assays arises
from structural similarity. Without an assumption of cor-
relation between structural and biological similarities for
these bioactive molecules, expected structural similarity
between bioactive molecules should not be very different
from that between biologically (and structurally) unrelatedmolecules. This idea is consistent with the small difference
in 3-D similarity scores between the NN-pairs and random
compound-compound pairs, as depicted in Figure 15. In
this context, the average similarity scores for the NI pairs
should also be similar to those for the NN-pairs and the
random pairs because the NI-pairs are biologically unre-
lated by nature, consistent with our previous study using
a single conformer per compound (also compared in
Figure 15). The multiple-conformer approach would
not make any noticeable difference of the NI-pair from
the NN pair and random pair “on average”, although
the present study did not consider the 3-D similarity
score computation of the NI pairs using the multiple-
conformer approach, as its proper treatment would
Figure 9 Per-AID shape-Tanimoto (ST)-optimized 3-D similarity average values. Binned distributions in 0.01 increments of the average 3-D
similarity scores for non-inactive–non-inactive (NN) pairs of 1,528 AIDs in the PubChem BioAssay database, computed at the shape-Tanimoto-
optimized superposition: (a) shape-Tanimoto (ST), (b) color-Tanimoto (CT), and (c) combo-Tanimoto (ComboT). “Single conformer”, “Multiple
conformers (all)”, and “Multiple conformers (best)” correspond to search scenarios A, B, and E, respectively (See Table 1).
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tional resources beyond our current means.
Discussion
An important question one may ask is: when you randomly
select two compounds an infinite number of times, what
does the distribution of their 3-D similarity scores look like?
This distribution may be used to develop a statistical ap-
proach to test the null hypothesis that a particular similarity
score between two compounds is likely to occur by chance.
The distribution curves in Figures 1 and 4, generated from
49,995,000 compound pairs (arising from 10,000 randomly
selected compounds), seem to be a good approximation
for this purpose. Considering that the distribution curves
from 270 billion compound pairs (arising from the 734-Kcompound set) for the single-conformer approach have
very similar distribution curves to those in Figure 1 with
identical averages and standard deviations (as summarized
in Table 3), the distribution curves from an infinite num-
ber of random compound pairs from a chemical data set
with a similar profile to PubChem’s is not likely to be very
different from those in Figure 1. We believe that the
50 million compound pairs from the 10-K set are also
enough for the multiple-conformer approach such that
adding more compound pairs in the distributions in
Figure 4 is not likely to change much. Therefore, we
generated a conversion map from a 3-D similarity score
between molecules to the p-value of getting that similarity
score by chance, based on the distributions from Figures 1
and 4 for the single conformer and ten conformers per
Figure 10 Per-AID color-Tanimoto (CT)-optimized 3-D similarity average values. Binned distributions in 0.01 increments of the average 3-D
similarity scores for non-inactive–non-inactive (NN) pairs of 1,528 AIDs in the PubChem BioAssay database, computed at color-Tanimoto-
optimized superposition: (a) shape-Tanimoto (ST), (b) color-Tanimoto (CT), and (c) combo-Tanimoto (ComboT). “Single conformer”, “Multiple
conformers (all)”, and “Multiple conformers (best)” correspond to search scenarios A, B, and E, respectively (See Table 1).
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were computed as 1 − percent cumulative distribution.]
There are two important factors that may affect the
results of the present study: the choice of biological assays
considered and the number of conformers used for each
compound. For example, one may argue that a much
clearer separation between the non-inactive and random
spaces (or between “active” and “inactive” spaces) could
have been observed if we considered assays with very well
established pharmacology, using an increasing num-
ber of conformers per compound. While it is possible
to do such analyses, it would be difficult to come up
with a generalization from them. From our analyses,
we already know that the per-AID NN-pair similarity
score averages (Figures 9, 10) show a broad distribu-
tion; while some are very close to the average for therandom compound pairs, others are much larger than
that. This is because nearly every assay in PubChem
is different from others in terms of various factors,
not just underlying pharmacology or binding geom-
etry. Therefore, even if we analyze some exceptional
cases with a huge number of conformers per compound,
we do not think it will be possible to extrapolate the results
to a general case. Indeed, many studies [15,16,32,52-55]
have tested various similarity methods using different data
sets, typically taking a few well-defined protein targets and
validated biological results, but no similarity method
showed the same performance against different protein tar-
gets tested. Moreover, considering that a substantial num-
ber of PubChem biological assays do not even have a clear
target protein, this “generalization from exception” does
not seem very promising.
Table 7 The cumulative count of biological assays whose non-inactive–non-inactive (NN) pairs have the average 3-D
similarity score smaller than a given threshold
ST-optimized CT-optimized
ST CT ComboT ST CT ComboT
Single conformer per compound
μ + σ 1339 (87.6) 1255 (82.1) 1289 (84.4) 1336 (87.4) 1309 (85.7) 1273 (83.3)
μ + 2σ 1490 (97.5) 1384 (90.6) 1425 (93.3) 1474 (96.5) 1410 (92.3) 1414 (92.5)
μ + 3σ 1517 (99.3) 1431 (93.7) 1460 (95.5) 1508 (98.7) 1440 (94.2) 1460 (95.5)
μ + 4σ 1528 (100.0) 1450 (94.9) 1494 (97.8) 1524 (99.7) 1463 (95.7) 1484 (97.1)
μ + 5σ − − 1468 (96.1) 1506 (98.6) 1528 (100.0) 1482 (97.0) 1503 (98.4)
μ + 6σ − − 1481 (96.9) 1514 (99.1) − − 1494 (97.8) 1511 (98.9)
μ + 7σ − − 1488 (97.4) 1517 (99.3) − − 1506 (98.6) 1516 (99.2)
μ + 8σ − − 1506 (98.6) 1528 (100.0) − − 1510 (98.8) 1528 (100.0)
μ + 9σ − − 1509 (98.8) − − − − 1516 (99.2) − −
μ + 10σ − − 1513 (99.0) − − − − 1519 (99.4) − −
μ + 11σ − − 1515 (99.1) − − − − 1526 (99.9) − −
μ + 12σ − − 1518 (99.3) − − − − 1528 (100.0) − −
μ + 13σ − − 1518 (99.3) − − − − − − − −
μ + 14σ − − 1527 (99.9) − − − − − − − −
μ + 15σ − − 1528 (100.0) − − − − − − − −
Ten conformers per compound
μ + σ 1389 (90.9) 1281 (83.8) 1275 (83.4) 1349 (88.3) 1332 (87.2) 1280 (83.8)
μ + 2σ 1500 (98.2) 1375 (90.0) 1407 (92.1) 1473 (96.4) 1400 (91.6) 1409 (92.2)
μ + 3σ 1527 (99.9) 1415 (92.6) 1447 (94.7) 1514 (99.1) 1436 (94.0) 1445 (94.6)
μ + 4σ 1528 (100.0) 1438 (94.1) 1469 (96.1) 1528 (100.0) 1462 (95.7) 1470 (96.2)
μ + 5σ − − 1462 (95.7) 1490 (97.5) − − 1480 (96.9) 1493 (97.7)
μ + 6σ − − 1474 (96.5) 1503 (98.4) − − 1488 (97.4) 1510 (98.8)
μ + 7σ − − 1486 (97.3) 1519 (99.4) − − 1499 (98.1) 1521 (99.5)
μ + 8σ − − 1492 (97.6) 1527 (99.9) − − 1518 (99.3) 1528 (100.0)
μ + 9σ − − 1501 (98.2) 1528 (100.0) − − 1521 (99.5) − −
μ + 10σ − − 1515 (99.1) − − − − 1528 (100.0) − −
μ + 11σ − − 1521 (99.5) − − − − − − − −
μ + 12σ − − 1521 (99.5) − − − − − − − −
μ + 13σ − − 1528 (100.0) − − − − − − − −
Symbols μ and σ represent the average and standard deviation of the respective 3-D similarity scores between randomly selected compounds (from Table 3).
Numbers in parentheses are the percent cumulative counts of biological assays. The single- and ten-conformer-per-compound values correspond to search
scenarios “A” and “E”, respectively.
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sensus on how many conformers are enough for 3-D
similarity methods. As pointed out in a recent review
by Scior et al. [12], to increase the reliability of the
3-D similarity comparison one must consider as many
conformations per compound as possible to ensure ad-
equate conformational space coverage. However, because
it would require enormous computational resources, one
should find a compromise between computational cost
and sampling breadth. The choice of the number of con-
formers per compound in our study is directly related tothe current capability and future direction of the PubChem
services. While PubChem generates up to 500 conformers
per compound, PubChem3D services provide support for
up to ten (diverse) conformers per compound for scalability
reasons and other considerations. The attempt here is to
see if one can build on top of this limitation a virtual
screening and biological data analysis platform with generic
purpose. Therefore, the scope of the present study was
determined based on this goal. While it is worth noting that
it is possible to devise a set of PubChem assays that give
definite clear separation of active and inactive space even
Figure 11 Deviation from random of per-AID shape-Tanimoto (ST)-optimized 3-D similarity average values. Deviation of the ST-
optimized 3-D similarity scores for non-inactive–non-inactive (NN) pairs of 1,528 AIDs from the corresponding average for the random compound
pairs, computed using both a single conformer and best multiple (ten) diverse conformers per compound: (a) ST-optimized ST, (b) ST-optimized
CT, and (c) ST-optimized ComboT. The deviations are binned with increment of 0.1 standard deviation (σ) unit. “Single” and “Multiple” refer to
search scenarios A and E, respectively (See Table 1).
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study identified [10], the focus of the present study is on
getting a big picture from very heterogeneous data in
PubChem. The statistical profiles of 3-D similarity values
for biologically tested compounds provided in this work
will enable other analysis approaches, such as clustering of
3-D similarity values at statistically-appropriate thresholds,
to identify useful subsets of non-inactive chemical struc-
tures involved in biological activity data trends, using a
limited number of diverse conformers per compound.
Conclusion
The present study investigated effects of using multiple
conformers per compound upon the 3-D similarity valuesused by PubChem. In the first part of this study, the 3-D
similarity score distribution curves were generated for the
unique conformer-conformer, conformer-compound, and
compound-compound pairs, using a single conformer
and ten diverse conformers for each of 10,000 ran-
domly selected compounds (Figures 1, 2, 3, 4 and Table 3).
When each conformer was treated like a unique compound
(i.e., the “all-conformer-pair” approach), the all-against-all
conformer comparison using ten diverse conformers
per compound resulted in similarity score distribu-
tions nearly identical to those computed with a single
conformer per compound. When similarity between
two compounds was represented using the largest
similarity score among possible conformer pairs arising
Figure 12 Deviation from random of per-AID color-Tanimoto (CT)-optimized 3-D similarity average values. Deviation of the CT-optimized
3-D similarity scores for non-inactive–non-inactive (NN) pairs of 1,528 AIDs from the corresponding average for the random compound pairs,
computed using both a single conformer and best multiple (ten) diverse conformers per compound: (a) CT-optimized ST, (b) CT-optimized CT,
and (c) CT-optimized ComboT. The deviations are binned with increment of 0.1 standard deviation (σ) unit. “Single” and “Multiple” refer to search
scenarios A and E, respectively (See Table 1).
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approach), the average similarity scores for randomly
selected compounds increased as a function of logarithmic
increase in the number of conformer pairs considered per
compound pair. The best-conformer-pair approach with
ten diverse conformers per compound resulted in the aver-
age random compound pair similarity score greater than
those computed using the single-conformer approach, by
0.11, 0.09, 0.15, 0.16, 0.07, and 0.18 for STST-opt, CTST-opt,
ComboTST-opt, STCT-opt, CTCT-opt, and ComboTCT-opt,
respectively.
Employing multiple conformers per compound also
affected the average and standard deviation of the per-
query similarity scores in a similar way (Figures 5, 6, 7).For example, while the all-conformer-pair approach
(Scenarios B and C) resulted in nearly identical average
per-query similarity scores to those from the single-
conformer approach (Scenario A), the “best-conformer-
pair” approach (Scenario D and E) increased the per-query
similarity scores. The average per-query scores for Scenarios
A, B and C were essentially identical to the average
for randomly selected compound pair (Figure 1), com-
puted using the single-conformer approach. The averages
for Scenario D and E were the same as those for the
unique conformer-compound pairs (Figure 3) and
the unique compound-compound pairs (Figure 4), re-
spectively, computed with multiple conformers per
compound.
Figure 13 Demonstrated multi-conformer effects using AID 1033. Effects of employing multiple conformers per compound upon 3-D
similarity of the non-inactive compounds tested in AID 1033. Eight compounds in panel (a) are non-inactive in AID 1033. Panel (b) depicts the
dendrogram that shows the 2-D similarity among the eight structures, computed using the PubChem subgraph fingerprints. The dendrograms
for the 3-D shape-optimized combo-Tanimoto (ComboTST-opt) similarity are shown in panels (c) and (d) for a single conformer per compound and
ten diverse conformers per compound, respectively. Panel (e) compares conformer superpositions between two of the non-inactive compounds
(CIDs 668798 and 1246750). LID stands for the local identifier, which represents different conformers of a compound.
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3-D similarity scores for the NN pairs (Figures 9 and 10)
was constructed for each of 1,528 bioassays archived in
PubChem, using the 156-K set and both the single-conformer and multiple-conformers per compound.
Whereas the average NN-pair 3-D similarity scores from
the all-conformer-pair and single-conformer approaches
did not differ very much from each other, the best-
Figure 14 Demonstrated multi-conformer effects using AID 491. Effects of employing multiple conformers per compound upon 3-D
similarity of non-inactive compounds tested in AID 491. Panel (a) shows the dendrogram based on 2-D similarity among eight compounds
selected from 60 non-inactive compounds in AID 491. The dendrograms for the 3-D shape-optimized combo-Tanimoto (ComboTST-opt) similarity
are shown in panels (b) and (c) for a single conformer per compound and ten diverse conformers per compound, respectively. Panel (d)
compares conformer superpositions between two of the non-inactive compounds (CIDs 490518 and 505938). LID stands for the local conformer
identifier, which represents different conformers of a compound.
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3-D similarity scores, compared to the single-conformer
approach. However, the magnitude of this increase wascomparable to those for the random compound pairs,
meaning that employing multiple conformers per com-
pound does not increase the separation between the
Figure 15 Summary comparison of overall average similarity. Comparison of the overall average 3-D similarity scores, μ[μ(XT)], for the non-
inactive–non-inactive (NN) pairs with those for the non-inactive–inactive (NI) pairs and random compound pairs. The words, “Single”, “Best”, and
“All”, in the legend box indicate the single-conformer approach (Scenario A), “best-conformer-pair” approach (Scenario E), and “all-conformer-pair”
approach (Scenario B), respectively. Study A is the present study, and Study B is a previous study by Kim et al. (Ref. [10]).
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the basis of these observations, it was inferred that the
multiple-conformer approach would not also result in a
noticeable separation between the NI- and NN-pairs
“on average”.
The present study is a critical step to understand
effects of conformational diversity of the molecules
upon the 3-D molecular similarity and its application to
aggregated biological assay data analysis. The results of
this study may be helpful to build search and analysis
tools that exploit 3-D molecular similarity between
compounds archived in PubChem and other molecular
libraries in a statistically meaningful way.
Methods
Datasets
The previous study [10] employed the 734-K set, con-
sisting of 734,485 biologically tested compounds with3-D information available, to investigate the distributions of
the 3-D similarity scores between randomly selected com-
pounds, using a single conformer per compound. However,
the 734-K set is so large that it is not currently practical to
employ multiple conformers for each molecule. Therefore,
the 10-K set (Additional file 1) was constructed by ran-
domly selecting 10,000 compounds from the 734-K set. As
shown in Table 1, the 10-K set and the 734-K set have
nearly identical average values and standard devia-
tions for various molecular properties, such as the
molecular volumes, steric shape quadrupole moments,
heavy atom count, and feature counts, and are com-
parable to the entire PubChem3D contents.
The 156-K set consists of 156,232 CIDs (Additional
file 2) that have 3-D information available and that are
declared as “non-inactives” in any assays archived in the
PubChem BioAssay database as of late January 2010
(ranging from AID 1 to AID 2310). [A non-inactive
Kim et al. Journal of Cheminformatics 2012, 4:28 Page 26 of 30
http://www.jcheminf.com/content/4/1/28molecule is defined as any molecule that is not in-
active against the assay target, including “unspecified/
inconclusive” compounds as well as “active” compounds].
This set was used to investigate the distribution of the 3-D
similarity scores between the NN pairs for a given assay.
For these per-assay analyses, it is desirable to exclude bioas-
says with too small number of non-inactives, because those
small-size assays may cause biased results. However, note
that the non-inactive count of a bioassay depends upon the
assay type. For example, while primary (high-throughput)
screenings typically may have up to thousands of non-inac-
tives, summary assays may have only a few non-inactives.
Because summary assays, which correspond to the last
stage of probe/lead discovery, are typically more accurate
than other assays, we wanted to include as many of them
in our analysis as possible. Therefore, it was necessary to
determine an appropriate non-inactive count thresh-
old (or a NN-pair count threshold) to exclude small-size
assays without losing too many summary assays. In our
previous study [10], bioassays with less than six NN pairs
or less than NI pairs were excluded, minimizing the loss of
summary assays. Similarly, the present study considered
1,528 bioassays with at least six NN pairs (Figure 8).
Note that the non-inactive compounds of these 1,528
bioassays include the inconclusive and unspecified com-
pounds as well as the active compounds. The reason for
using the non-inactive compounds instead of the active
compounds in our analysis is that the inconclusive and
unspecified compounds are indeed active in many
assays. The use of the non-inactive compounds some-
how reflects the heterogeneous nature of the PubChem
Bioassay data, because the activity outcome of the com-
pounds tested in PubChem bioassays is determined by
the individual depositors. This choice may raise a concern
especially when one is interested in a separation of the
“nominal” active space from the inactive space. Therefore, a
subset of the 1,528 assays were generated by selecting 843
assays which have active compounds only (without any
inconclusive or unspecified compounds), and the same ana-
lyses were performed both for the 1,528 assay set and the
843 assay set. The results from the 843 assay set are
included in Additional file 4. The similarity score distribu-
tions from the two assay sets have very similar averages and
standard deviations to each other, and hence, the conclu-
sions drawn from the 1,528 assay set should also be valid
for the 843 assay set.
Conformer models
The computed 3-D conformer models for compounds in
the 10-K and 156-K sets were downloaded from PubChem.
The PubChem3D conformer generation and sampling pro-
cedures are explained in detail in our recent studies
[6,11,56] and only a brief description is given below. The
PubChem3D conformer models are generated using theOMEGA software from the OpenEye Scientific Software,
Inc. In an initial stage, a maximum of 100,000 conformers
are generated for each chemical structure, using the Merck
Molecular Force Field (MMFF94s) minus the coulombic
terms, and an energy filter of 25 kcal/mol. If the chemical
structure has undefined stereo centers, a maximum of
100,000 conformers are generated for each of the stereo
isomers arising from enumeration of the undefined stereo
centers, and then combined together. [Therefore, a mol-
ecule with five undefined stereo centers will have 32 (= 25)
stereo isomers, resulting a maximum of 3.2 million confor-
mers being considered].
Because it is not practical to store all the conformers
and to use them efficiently, the conformer models are
down-sampled through conformer clustering with an
RMSD clustering threshold (RMSDthresh) determined by
the following equations:
RMSDthresh ¼ int 0:5þ RMSD
pred  5 
5
ð1Þ
RMSDpred ¼ 0:219þ 0:0099 NNHA þ 0:040 NER
ð2Þ
NER ¼ NR þ NNARA5 ð3Þ
where NNHA is the number of non-hydrogen (heavy)
atoms, NR is the number of rotatable bonds, NNARA is
the number of non-aromatic sp3-hybridized ring atoms,
and NER is the effective rotor count of a molecule, which
takes into account molecular flexibility due to rotatable
bonds and ring flexibility simultaneously. RMSDpred is
the predicted upper limit of the conformer model accu-
racy to ensure at least 90% of the PubChem3D con-
former models have at least one “bioactive” conformer
whose RMSD distance from the experimentally deter-
mined conformation is closer than RMSDpred. If the
conformer sampling with RMSDthresh, which is the
RMSDpred value rounded to the nearest 0.2 increment
[Equation (1)], results in more than 500 conformers for a
molecule, the RMSDthresh value is incremented by a further
0.2 and the conformer model is re-clustered. This process
is repeated as many times as necessary to restrict the overall
count of conformers to be 500 or less. This conformer sam-
pling stage reduces the size of the conformer models with-
out significant loss of the conformer model accuracy [56].
After conformer model sampling, a post processing
step is performed to completely relax the hydrogen
atom locations by performing an energy minimization
with all non-hydrogen atoms frozen. A subsequent "bump"
check removes any conformers that have MMFF94 atom-
atom interactions greater than 25 kcal/mol. Each con-
former is rotated and translated to their principal steric
axes (i.e., non-mass weighted principal moments of inertia
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conformer ordering gives a maximal description of the con-
formational space spanned by a molecule, if only a subset
of conformers are used.
Note that the conformers produced are not stationary
points on a potential energy hypersurface. Instead, the
PubChem3D conformer model for a chemical structure
is meant to represent all possible biologically-relevant
conformations that the molecule may have. In theory,
one should have a reasonable chance (~90%) to find any
biologically accessible conformation within the RMSD
sampling distance of the conformer model [6,56].
Although all of the (up to 500) conformers for each
molecule are accessible from the PubChem website
(http://pubchem.ncbi.nlm.nih.gov), only the first ten
“diverse” conformers per compound [11] are available
for public bulk download via the PubChem FTP site
(ftp://pubchem.ncbi.nlm.nih.gov). In addition, most search
and analysis tools provided by PubChem3D use up to ten
conformers per compound. Therefore, the present study
only considered the first ten diverse conformers for simi-
larity score computation.
ROCS-based similarity scores used in PubChem3D
Among many 3-D structure comparison approaches, Pub-
Chem uses ROCS [14,21] from the OpenEye Scientific Soft-
ware, Inc. Because ROCS uses atom-centered Gaussian
functions to describe the molecular shape [19,20], it can
perform a rapid shape superposition without a consid-
erable loss of accuracy, compared to when the hard-
sphere volumes is employed. In recent studies [15,57],
ROCS was shown to be comparable with, and often bet-
ter than, structure-based approaches in virtual screening,
both in terms of overall performance and consistency [17].
To quantify 3-D similarity between molecules, two
3-D similarity measures are used: shape-Tanimoto (ST)
[8,10,11,14,19-21] and color-Tanimoto (CT) [8,10,11,19,20].
The ST score is a measure of shape similarity, which is
defined as the following:
ST ¼ VAB
VAA þ VBB  VAB ð4Þ
where VAA and VBB are the respective self-overlap
volumes of conformers A and B and VAB is the overlap
volume between conformers A and B. The CT score,
given by Equation (5), quantifies the similarity of 3-D
orientation of protein-binding “features” between con-
formers, by checking the overlap of “fictitious” feature
atoms (also called “color” atoms) used to represent the
six types of functional groups considered: hydrogen-
bond donors, hydrogen-bond acceptors, cations, anions,













where: the index “f” indicates any of the six independent
fictitious feature atom types; VAA
f and VBB
f are the self-
overlap volumes of conformers A and B for feature atom
type f, respectively; and VAB
f is the overlap volume between
conformers A and B for feature atom type f. Additionally,
to consider shape similarity and feature similarity simultan-
eously, the two similarity metrics can be combined to cre-
ate a so-called combo-Tanimoto (ComboT) [10,11,19,20],
as specified by Equation (6):
ComboT ¼ ST þ CT ð6Þ
Because the ST and CT scores range from 0 (for no
similarity) to 1 (for identifical molecules) by definition, the
ComboT score ranges from 0 to 2 (without normalization
to unity, due to pre-existing convention). Two different
conformer superpositions are used: (1) the ST-optimized
(or shape-optimized) superposition, where the ST score be-
tween conformers is maximized, and (2) the CT-optimized
(or feature-optimized) superposition, where the CT
score between conformers is maximized. As a result,
PubChem3D quantifies 3-D molecular similarity using
six different scores: STST-opt, CTST-opt, ComboTST-opt,
STCT-opt, CTCT-opt, and ComboTCT-opt, where super-
scripts “ST-opt” and “CT-opt” indicate the ST-
optimization and CT-optimization, respectively.
3-D similarity score computation
The six 3-D similarity measures (i.e., STST-opt, CTST-opt,
ComboTST-opt, STCT-opt, CTCT-opt, and ComboTCT-opt)
were computed using the C++ Shape toolkit [20]. For
the 10-K set, a full (all-by-all) similarity matrix was com-
puted for each of the six similarity measures. However, it
was not practical to compute a full similarity score matrix
for the 156-K set using multiple conformers per compound.
Therefore, the 3-D similarity scores between two com-
pounds in the 156-K set were computed only when both
molecules were tested as non-inactives in at least one com-
mon bioassay. The computed similarity scores for each
conformer pair were stored with the translation/rotation
matrix that yields the corresponding alignment. The com-
puted similarity scores were extracted from the data files,
and histograms of the similarity scores were generated after
binning all similarity scores to their nearest 0.01 increment.
In the second part of this study, the average and
standard deviation of the 3-D similarity scores be-
tween the NN-pairs were computed for each of the
1,528 assays. These per-AID average and standard de-
viation are denoted with Greek letters μ and σ, respectively,
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tributions of the μ(XT) values for the 1,528 assays
considered in this study are shown in Figures 9 and 10, for
the ST-optimized and CT-optimized 3-D similarities,
respectively.
To investigate the multiple-conformer effect upon
the per-AID NN-pair similarity scores, it was neces-
sary to compare the 3-D similarity score distributions
from the single-conformer approach with those from
the multiple-conformer approach. Therefore, the aver-
age and standard deviation of the similarity score dif-
ference between two conformer models for a given
AID were computed using the following equations:
μ XTmultisingle











where “single” and “multi” indicate the type of conformer
models (i.e., the single-conformer or multiple-conformer
approach), and nsingle and nmulti are the number of the
compound pairs used in the single- and multiple-
conformer approaches, respectively, for a given assay. Be-
cause two different approaches (the best-conformer-pair
and all-conformer-pair approaches) were employed for the
multiple-conformer approach, subscripts “best” and “all”
are also used to distinguish them for clarification. Note
that nsingle and nmulti are not necessarily the same as each
other for a given assay, because the similarity score distri-
butions for the all-conformer-pair approach considers as
up to 100 times many conformer pairs as the single-
conformer approach.
When we refer to the average and standard deviation of a
set of the per-AID statistical parameters (e.g., over all the
1,528 AIDs), we use additional Greek letters μ and σ,
respectively, followed by the corresponding statistical para-
meters in brackets. For example, μ[μ(STbest−single
ST-opt )] and
σ[μ(STbest−single
ST-opt )] indicate the overall average and standard
deviation of μ(STbest−single
ST-opt ) over a set of AIDs. Note that
the standard deviation for the μ(XT) and σ(XT) values
(i.e., σ[μ(XT)] and σ[σ(XT)]) were computed using the
following equations:
σ μ XTð Þ½  ¼
ﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃXN
i
μi XTð Þ  μ μ XTð Þ½ ð Þ2
N  1
vuuuut ð9Þσ σ XTð Þ½  ¼
ﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃXN
i
σ i XTð Þ  μ σ XTð Þ½ ð Þ2
N  1
vuuuut ð10Þ
where μi(XT) and σi(XT) are the average and standard
deviation of the NN-pair similarity scores for an assay
i and N is the number of assays considered.
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Additional file 1: 10-K CID set. A list of 10,000 CIDs, used for
construction of the 3-D similarity score distributions for the random
compound pairs.
Additional file 2: 156-K CID set. A list of 156,232 CIDs, used to
investigate the NN-pair 3-D similarity scores on the per-assay basis.
Additional file 3: Similarity Scores. A tab-delimited file that contains
statistical parameters of the NN-pair 3-D similarity scores for each of 1,528
AIDs considered for per-assay analysis.
Additional file 4: Analysis of the 843 assays. Supplementary figures
and tables that summarize the results from the 843 assays that have
active compounds only (without any inconclusive or unspecified
compounds).
Additional file 5: Conversion map from the 3-D similarity score to
the p-value. An excel file that contains the conversion maps from a 3-D
similarity score between molecules to the p-value of getting that score
by chance.
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